Open an account

LeMaitre Vascular

LMAT · NASDAQ

$83.40+$1.09 (+1.32%)TodayMarket closed ·
Prev close $82.31

About LMAT

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 646 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. The company also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.

Employees
646
Headquarters
Burlington, Massachusetts
Listed
Oct 19, 2006
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
lemaitre.com

LMAT key statistics

Market cap
1.88B
Price-earnings ratio
28.88
Dividend yield
1.11%
Average volume
264.75K
Volume
145.38K
Open price
$83.16
High today
$83.90
Low today
$82.84
52 Week high
$118.01
52 Week low
$78.22

LeMaitre Vascular (LMAT) at a glance

As of Oct 20, 2026, LeMaitre Vascular (LMAT) shares are priced at $83.40, giving the company a market cap of 1.88B, a price-to-earnings ratio of 28.88 and a dividend yield of 1.11%.

Today the stock has traded between $82.84 and $83.90. The current price is 0.7% above the day's low and 0.6% below its high.

Volume so far is 145.38K shares, below the average of 264.75K shares a day.

Over the past year LeMaitre Vascular has ranged from $78.22 to $118.01, and now sits 13% of the way up that range.

LeMaitre Vascular met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.74 per share against an estimate of $0.8229.

The average analyst price target is $109.14, 30.9% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 4 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 9 analystsAvg $109.14
Low
$81.81
Now
$83.40
High
$138.60

LMAT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 4.6% on average.

  1. Q3 FY24: reported $0.49 per share against an estimate of $0.4437
  2. Q4 FY24: reported $0.49 per share against an estimate of $0.5026
  3. Q1 FY25: reported $0.48 per share against an estimate of $0.5081
  4. Q2 FY25: reported $0.60 per share against an estimate of $0.578
  5. Q3 FY25: reported $0.62 per share against an estimate of $0.5774
  6. Q4 FY25: reported $0.68 per share against an estimate of $0.6772
  7. Q1 FY26: reported $0.68 per share against an estimate of $0.6742
  8. Q2 FY26: reported $0.74 per share against an estimate of $0.8229

LMAT news

  • Press releasePRNewswire

    LeMaitre Vascular Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is Exposed

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • LeMaitre Vascular Reports Q1 2026 Results: Full Earnings Call Transcript

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Exploring LeMaitre Vascular's Earnings Expectations

  • Earnings Scheduled For November 6, 2025

  • Where LeMaitre Vascular Stands With Analysts

Similar companies

Companies in the same industry as LeMaitre Vascular

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.